557 related articles for article (PubMed ID: 37828829)
21. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
22. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
[TBL] [Abstract][Full Text] [Related]
23. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
24. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
25. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
Frías JP
Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Kimura T; Katakura Y; Shimoda M; Kawasaki F; Yamabe M; Tatsumi F; Matsuki M; Iwamoto Y; Anno T; Fushimi Y; Kamei S; Kimura Y; Nakanishi S; Mune T; Kaku K; Kaneto H;
Diabetes Obes Metab; 2023 Dec; 25(12):3632-3647. PubMed ID: 37646192
[TBL] [Abstract][Full Text] [Related]
27. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
Yang Y; He L; Liu P; Wang J; Yang N; Li Z; Ping F; Xu L; Li W; Zhang H; Li Y
Diabetes Obes Metab; 2024 Feb; 26(2):548-556. PubMed ID: 37860884
[TBL] [Abstract][Full Text] [Related]
28. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
Chen H; Li XZ; Chen JQ; Ren TS; Zhang YS; Wang YN; Zhao QC
Medicine (Baltimore); 2023 Jul; 102(27):e34122. PubMed ID: 37417602
[TBL] [Abstract][Full Text] [Related]
30. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
Crabtree TSJ; Adamson K; Reid H; Barnes D; Sivappriyan S; Bickerton A; Gallen IW; Field BCT; Idris I; Ryder REJ;
Diabetes Obes Metab; 2022 Jul; 24(7):1398-1401. PubMed ID: 35322528
[TBL] [Abstract][Full Text] [Related]
31. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Gogineni P; Melson E; Papamargaritis D; Davies M
Expert Opin Pharmacother; 2024 May; 25(7):801-818. PubMed ID: 38753454
[TBL] [Abstract][Full Text] [Related]
32. Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.
Patoulias D; Popovic DS; Stoian AP; Janez A; Sahebkar A; Rizzo M
J Diabetes Complications; 2023 Aug; 37(8):108529. PubMed ID: 37301063
[TBL] [Abstract][Full Text] [Related]
33. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
34. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
35. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
Rivera FB; Lumbang GNO; Gaid DRM; Cruz LLA; Magalong JV; Bantayan NRB; Lara-Breitinger KM; Gulati M; Bakris G
Diabetes Obes Metab; 2024 Jun; 26(6):2209-2228. PubMed ID: 38505997
[TBL] [Abstract][Full Text] [Related]
37. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
38. Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
Osonoi T; Oura T; Hirase T
Diabetes Obes Metab; 2024 Jan; 26(1):126-134. PubMed ID: 37794628
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus].
Khamnueva LY; Andreeva LS
Probl Endokrinol (Mosk); 2023 May; 69(2):38-46. PubMed ID: 37448270
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
Kaku K; Yamada Y; Watada H; Abiko A; Nishida T; Zacho J; Kiyosue A
Diabetes Obes Metab; 2018 May; 20(5):1202-1212. PubMed ID: 29322610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
